SCHEMBL2097150

SCHEMBL2097150

COc1ccc(CO)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 2/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
MAPT P10636 2/20 0.55
MAPK10 P53779 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.53
POLB P06746 1/20 0.53
TTR P02766 2/20 0.51
HPGD P15428 1/20 0.51
THRB P10828 1/20 0.50
RORC P51449 1/20 0.50
HSD17B10 Q99714 2/20 0.49
GAA P10253 1/20 0.47
TP53 P04637 1/20 0.47
XBP1 P17861 1/20 0.47
HTT P42858 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.46
CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29524881 1.00 MEN1 (0.56) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL7611761 0.85 MEN1 (0.53) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL1548047 0.84 NPC1 (0.53) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL4976340 0.83 TTR (0.67) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL6427782 0.83 KMT2A (0.55) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL26641603 0.82 TNKS2 (0.51) MEN1KMT2AALDH1A1SMN1; SMN2POLB
SCHEMBL1373688 0.82 KMT2A (0.57) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL28170408 0.81 CA2 (0.68) ALDH1A1NPC1RAB9AMAPTPOLB
SCHEMBL29997296 0.81 CA2 (0.68) ALDH1A1NPC1RAB9AMAPTPOLB
SCHEMBL119395 0.81 CA2 (0.68) ALDH1A1NPC1RAB9AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559582-B2 Polyacrylate polymer BASF SE (DE) 2026-02-24 US claimed
EP-3898730-A1 POLYACRYLATE POLYMER BASF SE (DE) 2021-10-27 EP claimed
CN-113195564-A Polyacrylate polymers 巴斯夫欧洲公司 2021-07-30 CN claimed
WO-2020127463-A1 POLYACRYLATE POLYMER BASF SE (DE) 2020-06-25 WO claimed
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 US disclosed
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY THE UNIVERSITY OF TOLEDO (US) 2026-04-23 US disclosed
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
US-12559582-B2 Polyacrylate polymer BASF SE (DE) 2026-02-24 US disclosed
US-12521397-B2 Nucleotide analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-13 US disclosed
US-12350274-B2 Nucleotide analogs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-07-08 US disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 EP disclosed
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed
EP-1277741-A1 CYCLIC COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-01-22 EP disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1223170-A1 PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-07-17 EP disclosed
EP-1196391-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-17 EP disclosed
WO-2001005770-A1 BENZIMIDAZOLONE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-25 WO disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
US-4525304-A Process for preparing oxazolinoazetidinones ELI LILLY AND COMPANY (US) 1985-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559582-B2 Polyacrylate polymer SAAL1, ATXN2L, VCL MEN1 3341/4885KMT2A 3634/4885ALDH1A1 508/4885
US-12350274-B2 Nucleotide analogs NUDT1, DUT, DPYD MEN1 2325/4885KMT2A 2505/4885ALDH1A1 1445/4885
US-20260109674-A1 ALLOSTERIC MODULATION OF MUSCARINIC ACETYLCHOLINE RECEPTOR EFFICACY CHRM5, CHRM3, CHRNA3 MEN1 4117/4885KMT2A 3712/4885ALDH1A1 2558/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MEN1 4588/4885KMT2A 4179/4885ALDH1A1 339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.